{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:07:30Z","timestamp":1791986850379,"version":"4.4.0"},"reference-count":29,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410) evaluated efficacy and safety of LAN\/TMZ in progressive T-NETs. Methods: ATLANT was a 12-month, Italian, phase 2, single-arm, open-label, multicenter pilot study. Eligible patients had unresectable, locally advanced\/metastatic, well-\/moderately differentiated T-NETs with radiological progression. Patients received subcutaneous LAN 120 mg every 28 days and oral TMZ 250 mg\/day for 5 consecutive days every 28-day cycle. Main endpoints are disease control rate (DCR) at 9 months (primary; investigator-assessed), median progression-free survival (PFS), biomarkers, and safety. Results: The number of patients was 40; 60% were male. Primary tumor site was lung (90%) and thymus (10%). Carcinoid type was typical (20.0%) and atypical (52.5%). DCR at 9 months was 35.0% (95% confidence interval (CI) 20.63\u201351.68; nonacceptability threshold \u226410%, p &lt; 0.0001; not significantly above clinically relevant threshold \u226530%, p = 0.2968). DCR between 7.5 and 10.5 months (sensitivity analysis) was 45.0% (95% CI: 29.26\u201361.51) and clinically relevant (p = 0.0320 at \u226530% threshold). Median PFS was 37.1 (95% CI: 24.1\u201352.9) weeks. No association was observed between biomarker variations (chromogranin A, neuron-specific enolase, somatostatin receptor type-2, Ki-67, 6-O-methylguanine-DNA-methyl-transferase) and DCR or PFS. Most patients (97.5%) had treatment-emergent adverse events (TEAEs); 72.5% had treatment-related TEAEs. TEAEs were mainly grade 1\/2. No unanticipated TEAEs were reported. Conclusions: This study showed that the LAN\/TMZ combination has promising efficacy in progressive T-NETs, and was well tolerated. Larger studies are warranted to support the clinical benefits of LAN\/TMZ in patients with T-NETs.<\/jats:p>","DOI":"10.1159\/000526811","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T17:00:31Z","timestamp":1661965231000},"page":"332-342","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study"],"prefix":"10.1159","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-9514","authenticated-orcid":false,"given":"Piero","family":"Ferolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3956-0043","authenticated-orcid":false,"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-0798","authenticated-orcid":false,"given":"Francesca","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Marconcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-5703","authenticated-orcid":false,"given":"Vito","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"La Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-3946","authenticated-orcid":false,"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Volante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ghizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mazzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0704","authenticated-orcid":false,"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds295"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123049"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1354984"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.04.03"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1316158"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4158\/ep151172.or"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30681-2"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv041"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.003"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000402752"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1108"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2000.12.5.421"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2053"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000354760"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000365514"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13427"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0276"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx193"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0217"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0287"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0246"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000092"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25035"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605796"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1476"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02475-2"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/nen\/article-pdf\/113\/3\/332\/3962689\/000526811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/nen\/article-pdf\/113\/3\/332\/3962689\/000526811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:19:40Z","timestamp":1745407180000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000526811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,3,7]]}},"URL":"https:\/\/doi.org\/10.1159\/000526811","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.20748082","asserted-by":"subject"}]},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}